Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.40 |
| ▸ | MAOB | P27338 | 7/20 | 0.40 |
| ▸ | KDM1A | O60341 | 7/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28556134 | 0.86 | TACR3 (0.41) | MAOAMAOBKDM1AHSD11B1MEN1 | |
| SCHEMBL29214271 | 0.82 | HSD11B1 (0.41) | MAOAMAOBKDM1AHSD11B1MEN1 | |
| SCHEMBL923461 | 0.77 | MAOA (0.48) | MAOAMAOBHSD11B1SLC6A2SLC6A4 | |
| SCHEMBL22493574 | 0.74 | GRM5 (0.41) | HSD11B1MEN1KMT2AGRIN2BHPGD | |
| SCHEMBL22493573 | 0.74 | GRM5 (0.41) | HSD11B1MEN1KMT2AGRIN2BHPGD | |
| SCHEMBL22493575 | 0.74 | GRM5 (0.41) | HSD11B1MEN1KMT2AGRIN2BHPGD | |
| SCHEMBL2573934 | 0.74 | MAOA (0.41) | MAOAMAOBHSD11B1SLC6A2SLC6A4 | |
| SCHEMBL3716772 | 0.74 | MAOA (0.45) | MAOAMAOBHSD11B1MEN1KMT2A | |
| SCHEMBL13818225 | 0.74 | LMNA (0.43) | MAOAMAOBHSD11B1KMT2ASLC6A2 | |
| SCHEMBL5818358 | 0.74 | AKR1C1 (0.47) | MAOAMAOBMEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | MAOA 1465/4885MAOB 1306/4885KDM1A 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.